NR4A1 and breast cancer: Patients with tumors with alterations in the PI3K/AKT pathway showed in particular a survival disadvantage in the advanced-stage hormone receptor+/HER2– BC subtype (HR, 1.38 [95% CI, 0.95 to 1.38]; P = .014; Fig 3E).